Sellas Life Sciences Group Inc (SLS)

NASDAQ
1.68
+0.11(+7.01%)
After Hours
1.68
0.00(0.00%)
- Real-time Data
  • Volume:
    149,376
  • Day's Range:
    1.59 - 1.70
  • 52 wk Range:
    1.17 - 5.58

SLS Overview

Prev. Close
1.57
Day's Range
1.59-1.7
Revenue
-
Open
1.59
52 wk Range
1.17-5.58
EPS
-1.67
Volume
149,376
Market Cap
47.62M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
347,030
P/E Ratio
-1.00
Beta
2.25
1-Year Change
-43.24%
Shares Outstanding
28,347,920
Next Earnings Date
Aug 17, 2023
What is your sentiment on Sellas Life Sciences?
or
Market is currently closed. Voting is open during market hours.

Sellas Life Sciences Group Inc Company Profile

Sellas Life Sciences Group Inc Company Profile

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in 20 or more cancer types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications. The Company is also developing GFH009, a small molecule, selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Read More

Analyst Price Target

Average6.00 (+257.14% Upside)
High9.00
Low3.00
Price1.68
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong SellStrong BuyStrong BuyBuyStrong Sell
SummarySellStrong BuyStrong BuyBuyStrong Sell
  • will go up now to 2.4🚀🚀🚀
    1
    • gains
      0
      • cannot see it on its chart
        0
    • To clarify, this is a report for alignant pleural mesothelioma (MPM). which is in the first stageThe report for Acute Myeloid Leukemia (AML) which is in the third phase is coming out by the end of June. you have to wait, for now everything is ok
      1
      • Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeksNew and Updated Clinical and Translational Data Expected by End of Q4 2021NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced encouraging updated clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo®) in patients with macroscopic (measurable) deposits of malignant pleural mesothelioma (MPM).
        0
        • very good test results
          0
          • 👍👍
            0
            • soon going to 30-50
              0
              • Russel microcap index add.... Good...
                0
                • Been in this from $2 21000shares I believe life changer
                  0
                  • oll
                    0